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Clinical heterogeneity in familial Alzheimer’s disease
Two studies of non-amnestic manifestations of 
autosomal dominant familial Alzheimer’s disease 
(ADAD) are reported in The Lancet Neurology.1,2 In the 
ﬁ rst study, Mengxuan Tang and colleagues1 report, on 
behalf of the Dominantly Inherited Alzheimer Network 
(DIAN) consortium, a combined description of the 
DIAN observational study (DIAN-OBS) cohort and the 
scientiﬁ c literature.1 In the second study, Natalie Ryan 
and colleagues2 describe heterogeneous cognitive 
symptoms and neurological features in a large series 
of participants that were referred to the Dementia 
Research Centre in London, UK, over many years.
Tang and colleagues1 compare individual data from 
1228 patients with ADAD (753 with detailed clinical 
data) with data from the DIAN-OBS cohort. They found 
that non-cognitive features, such as myoclonus and 
seizures, were commonly observed in patients reported 
on in the published work (each in approximately one of 
ﬁ ve patients). By contrast, motor features were far less 
common in the 107 symptomatic patients in the DIAN-
OBS cohort (9% had myoclonus and 3% had seizures). 
Findings were inverted for non-amnestic cognitive 
symptoms: atypical presentations of aphasia, visual 
agnosia, and behavioural changes were quite common 
in the DIAN-OBS cohort (>50%) but were far more rare 
in the patients described in the published work (<30%). 
Ryan and colleagues2 describe a large case series of 
213 patients with PSEN1 or APP mutations (detailed 
medical history was available for 121 only). Myoclonus 
and seizures were the most common non-cognitive 
neurological features, with myoclonus—observed in 
33% of individuals with APP mutations and 47% of 
individuals with PSEN1 mutations—being a signiﬁ cant 
risk factor for seizures (occurring in about one in four 
patients). Individuals with APP mutations almost 
invariably had amnestic presentations (97%); by 
contrast, amnestic symptoms were signiﬁ cantly less 
common in patients with PSEN1 mutations (84%; 
p=0·037). Of note, even though Ryan and colleagues 
describe the non-amnestic presentations in patients 
with PSEN1 mutations as common, these non-amnestic 
presentations were far less common in their case series 
(16% in PSEN1, 3% in APP) than in DIAN-OBS (>50%). 
As such, Ryan and colleagues’ case series is similar to 
as described in the analysis of the literature by Tang 
and colleagues. It is not evident what explains these 
diﬀ erences, but methodological aspects, particularly 
selection bias and measurement bias,3 probably 
contribute to the diﬀ erence in observed prevalence, as 
noted by both groups of authors. 
Both Articles share the important message that 
recognising clinical heterogeneity in Alzheimer’s 
disease is crucial. An accurate diagnosis is of great 
importance because this is the starting point for best 
patient management. Heterogeneity in Alzheimer’s 
disease needs to be recognised because diagnoses 
are too often missed in patients with atypical 
presentations, and understanding heterogeneity might 
provide keys to ﬁ nding treatments. Also, a substantial 
proportion of patients with sporadic Alzheimer’s 
disease have non-amnestic presentations, such as 
visual agnosia, aphasia, or dysexecutive or behavioural 
phenotypes.4–6 Clinicians should be aware that memory 
can be relatively spared in Alzheimer’s disease until 
advanced stages of the disease. Particularly in patients 
with an atypical presentation or an atypical age 
at onset, diagnosis is often missed because many 
professionals do not think of Alzheimer’s disease when 
they see a 50 year old complaining of losing track of 
deadlines at work or having diﬃ  culty mastering a 
novel software package. The likelihood of an atypical 
presentation gradually increases with a younger age 
at onset.7 Patients with an onset later than 80 years 
typically present with early and prominent amnestic 
problems, but in those with an onset before the age of 
65 years, atypical presentations occur in roughly one of 
three patients.8,9 
The latest diagnostic criteria reﬂ ect these ﬁ ndings; the 
National Institute on Aging—Alzheimer’s Association 
(NIA-AA) criteria and the International Working Group 
(IWG) criteria no longer require memory impairment 
for a clinical diagnosis of Alzheimer’s disease, as they 
recognise that Alzheimer’s disease might also start with 
deﬁ cits in other cognitive domains.10,11 Additionally, the 
NIA-AA criteria list changes in personality, behaviour, 
or comportment as a ﬁ fth cognitive domain. These 
criteria ﬁ t the observations in the study by Tang and 
colleagues, who observed changes in personality and 
behaviour in 61% of the DIAN participants and 32% of 
the cases described in the published work. However, a 
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drawback of listing these changes as a ﬁ fth cognitive 
domain is that it is quite diﬃ  cult to establish norms or 
cut oﬀ s. When is behaviour so abnormal that it should 
count as an impaired domain on which to establish 
a diagnosis of dementia? In the course of dementia, 
almost every patient encounters behavioural problems 
to some extent, which might be intrinsically caused by 
the disease process or be a reaction their experience of 
ongoing decline. By contrast to changes in cognition, 
behavioural impairment does not show a monotonic 
decline with the disease process, but rather has a sinoid-
like course. For example, a patient might experience 
depression early on, but, as the disease progresses, 
their mood may actually lift. Additionally, behavioural 
symptoms come and go over the course of disease, and 
symptoms such as delusions or aberrant motor activity 
might develop at any time. Neither the NIA-AA or IWG 
criteria mentions non-cognitive neurological features in 
the diagnosis of Alzheimer’s disease, other than in the 
context of mixed dementia due to stroke or Lewy body 
pathology. These neurological features seem to only 
present in a later stage of the disease and hence are of 
less relevance for diagnosis.
Heterogeneity in manifestation might reﬂ ect 
variation in underlying molecular pathways, and 
disentangling the various routes to dementia due to 
Alzheimer’s disease could ultimately lead to diﬀ erent 
therapeutic strategies tailored to speciﬁ c patient 
groups. As a ﬁ rst possibility, the heterogeneity in 
clinical presentation might be due to mixed pathology. 
For example, in late-onset Alzheimer’s disease mixed 
disease is the norm rather than the exception, and co-
occurring Lewy body pathology or vascular pathology 
might contribute to clinical heterogeneity. If patients 
present with mixed disease, it would seem logical 
to target treatment for each of the contributing 
pathologies, rather than base treatment strategies 
on the prevailing clinical diagnosis alone.12 However, 
mixed disease cannot be the only explanation for 
clinical heterogeneity. This is illustrated by the fact 
that clinical heterogeneity is even more common in 
patients with an early age of onset, and within the 
spectrum of Alzheimer’s disease, vulnerability of brain 
regions to disease seems to vary among patients. For 
example, although most patients with Alzheimer’s 
disease have a predominantly temporal distribution of 
pathology, pathology is more posterior in others.
These studies1,2 support this idea that even 
monogenetic forms of the disease do not present 
with one uniform manifestation. Although Tang and 
colleagues report that mutation type was related in 
some extent to variation in age at onset and Ryan 
and colleagues report an association with likelihood 
of atypical cognitive symptoms, this did not explain 
a large proportion of the observed heterogeneity. 
Instead, the origin of the observed variability in 
pathology could lie in other factors (eg, environmental, 
metabolic, or epigenetic). A second possibility is that 
the heterogeneity observed in these two studies 
does have a genetic origin, with genes other than the 
major causative ones contributing to variations in 
vulnerability of speciﬁ c brain regions. As an example, 
former studies have suggested that APOE ε4-negative 
patients are more likely to present with atypical 
cognitive symptoms.7 Developmental factors might 
also contribute to regional vulnerability. For example, 
individuals that had language learning disability as 
a child might be more prone to have a logopenic 
progressive aphasia related to Alzheimer’s disease at a 
later age.13 This notion would ﬁ t with the general idea 
that the strength of speciﬁ c neural networks not only 
lie at the heart of variability in regional vulnerability,14–16 
but also that strengthening speciﬁ c neural networks 
might be at the core of resilience to pathology, and, as 
such, provide a target for treatment. 
The notion that we will ﬁ nd one treatment that cures all 
patients with Alzheimer’s disease is quickly losing ground. 
Far more likely is the idea that in the future, speciﬁ c 
subtypes of Alzheimer’s disease could beneﬁ t from 
speciﬁ c medications. To attain that goal, recognition 
and deep understanding of heterogeneity in clinical 
manifestation of Alzheimer’s disease is a necessary step. 
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assumed to be similar to searching for the Holy Grail. 
The term consciousness has many ambiguous meanings 
and often, in medicine, awareness or responsiveness (or 
lack thereof) are used as surrogate markers. Epileptic 
seizures provide an opportunity to study these types of 
changes as part of the consciousness experience. In the 
Lancet Neurology, Jennifer Guo and colleagues1 report the 
results of their study aimed at discovering the potential 
neuronal underpinnings of impaired consciousness, as 
d epicted by alterations in awareness or responsivity, 
in presumed typical absence epilepsy using functional 
MRI (fMRI) and electroencephalography (EEG), 
and behavioral testing in children and adolescents 
aged 5–19 years. The investigators propose that the 
impairments identiﬁ ed are the result of widespread 
involvement of the brain, implicating suspension of 
the default mode network in conjunction with reduced 
sensory perception, and not because of focal changes. 
They also suggest that the behavioural impairments 
might happen at the onset of the seizures. 
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investigators expanded the criteria for absence 
seizures and probably included patients with diﬀ erent 
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